Imricor Announces Development Agreement with MIPM

Karen BorresenNews

31 March 2022 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. MIPM is headquartered in Mammendorf, Germany.

Performing cardiac ablation of complex arrythmia, such as VT, requires an external cardioverter defibrillator. MIPM has developed such a system. 

Imricor’s Vice President of Marketing and Business Development, Nick Twohy, said: “We are thrilled to be aligned with a world leader in providing MRI-compatible devices. MIPM’s defibrillator and technology are critical to the success of performing complex iCMR ablations.”

Under the terms of the agreement, Imricor and MIPM will collaborate on product development and clinical trials, including Imricor’s upcoming trial for expanded indications to VT ablation procedures in the iCMR.

MIPM MRI-Compatible Defibrillator

Andreas Klement, Vice President, MIPM, stated, “MIPM is very happy about the cooperation with Imricor and expects a long-term and fruitful cooperation in this innovative field of electrophysiological examinations and ablation procedures in the MR-Environment.”

~ ~ ~ ~ ~
About Imricor